Ameriprise
VRDN icon

Ameriprise’s Viridian Therapeutics VRDN Stock Holding History

Ameriprise’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$538K Buy
29,283
+6,502
+29% +$105K ﹤0.01% 3641
2026
Q1 		$446K Sell
22,781
-352
-2% -$10.5K ﹤0.01% 3631
2025
Q4 		$720K Buy
23,133
+95
+0.4% +$2.61K ﹤0.01% 3482
2025
Q3 		$497K Sell
23,038
-93
-0.4% -$1.68K ﹤0.01% 3628
2025
Q2 		$323K Sell
23,131
-35,140
-60% -$477K ﹤0.01% 3670
2025
Q1 		$785K Buy
58,271
+9,478
+19% +$161K ﹤0.01% 3303
2024
Q4 		$935K Buy
48,793
+6,806
+16% +$148K ﹤0.01% 3269
2024
Q3 		$955K Buy
41,987
+21,002
+100% +$343K ﹤0.01% 3240
2024
Q2 		$273K Buy
+20,985
New +$290K ﹤0.01% 3612
2023
Q1 		– Sell
-267,765
Closed -$7.82M – 4038
2022
Q4 		$7.82M Buy
+267,765
New +$6.17M ﹤0.01% 1952

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.75B AUM 68.58% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
KCM
Kynam Capital Management Princeton, New Jersey $1.81B AUM 192.15% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.51B AUM 546.08% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Ameriprise's VRDN Position: Q2 2026 in Review

Ameriprise increased its Viridian Therapeutics (VRDN) stake by 29% in Q2 2026, buying an estimated $105K and bringing the position to 29,283 shares worth $538K. The position accounts for ﹤0.01% of the portfolio, ranked #3641.

Ameriprise first reported a position in VRDN in Q4 2022 and has held it in 10 quarters since. The position peaked at $7.82M in Q4 2022. 214 funds tracked by Wall St. Rank hold VRDN as of Q2 2026.

  • Ameriprise held 29,283 shares of Viridian Therapeutics worth $538K as of Q2 2026.
  • Ameriprise bought 6,502 Viridian Therapeutics shares in Q2 2026, an estimated $105K.
  • Viridian Therapeutics made up ﹤0.01% of Ameriprise's portfolio in Q2 2026, its #3641 holding.
  • Ameriprise first reported a position in Viridian Therapeutics in Q4 2022 and has held it in 10 quarters since.
  • Ameriprise's Viridian Therapeutics position peaked at $7.82M in Q4 2022.
  • 214 funds tracked by Wall St. Rank held Viridian Therapeutics as of Q2 2026.

Based on Ameriprise's 13F filing for Q2 2026, filed 14 Aug 2026.